Renal cell cancer after kidney transplantation
- 148 Downloads
This study aims to identify modifiable risk factors for de novo renal cell carcinoma (RCC) after kidney transplantation in a matched-pair approach matching for unmodifiable factors.
Patients and methods
One thousand six hundred fifty-five adults who underwent kidney transplantation in the period 1 January 2000 to 31 December 2012 were analyzed. Patients with RCC after kidney transplantation were matched in a 1:2 ratio with those without RCC using the indication for transplantation, age at transplantation (± 10 years), recipient sex (male/female), number of received transplants, living organ donor transplantation (yes/no), and time of follow-up in days as matching criteria. The paired t test was used to compare continuous variables and the Cochran-Mantel-Haenszel test for categorical variables. Multivariable conditional logistic regression modeling was used to identify independent risk factors for RCC.
In matched-pair analysis, a total number of 26 incident cases with RCC after kidney transplantation could be matched. Post-transplant RCC was significantly associated with longer durations of pre-transplant hemodialysis (p = 0.007) and post-transplant immunosuppression with cyclosporine (p = 0.029) and/or mycophenolate mofetil (p = 0.020) and with larger proportions of post-transplant time on mycophenolate mofetil (p = 0.046) and/or prednisolone medication (p = 0.042). Multivariable conditional logistic regression modeling revealed a significant risk increasing multiplicative factor interaction between the duration of pre-transplant dialysis (years) and the time of prednisolone usage (percent/100). Cyclosporine A usage and mycophenolate mofetil usage were also revealed as independent, significant risk factors for RCC development.
Longer pre-transplant dialysis, cyclosporine-based protocols and/or intensified immunosuppression with additional mycophenolate mofetil, and larger proportions of time of prednisolone treatment during follow-up increase de novo RCC risk.
KeywordsRenal cell cancer Renal transplantation Immunosuppression Hemodialysis Cyclosporine
Sources of financial support
This work was supported by a grant from the German Federal Ministry of Education and Research (reference number 01EO1302).
Study conception and design: Dennis Kleine-Döpke, Matthias Oelke, and Harald Schrem. Acquisition of data: Dennis Kleine-Döpke, Matthias Oelke, Ysabell Schwager, and Harald Schrem. Analysis and interpretation of data: Dennis Kleine-Döpke, Matthias Oelke, and Harald Schrem. Drafting of manuscript: Dennis Kleine-Döpke, Matthias Oelke, and Harald Schrem. Critical revision of manuscript: Dennis Kleine-Döpke, Matthias Oelke, Anke Schwarz, Ysabell Schwager, Frank Lehner, Jürgen Klempnauer, and Harald Schrem.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Ethics Committee of Hannover Medical School approved this retrospective study (approval decision number 2706-2015).
Informed consent was obtained from all individual participants included in the study. Patients provided informed consent that their data may be used for scientific purposes at the time of hospital admission which is the general policy of our institution.
- 1.Kaatsch P, Spix C, Hentschel S et al (2013) Krebs in Deutschland 2009/2010. 9. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Ruksaldruck, Berlin, ISBN 978-3-89606-221-5Google Scholar
- 2.Barnes B, Bertz J, Buttmann-Schweiger N et al (2016) Bericht zum Krebsgeschehen in Deutschland, Zentrum für Krebsregisterdaten im Robert Koch-Institut (Hrsg), Ruksaldruck, Berlin, ISBN: 978-3-89606-279-6. https://doi.org/10.17886/rkipubl-2016-014
- 5.Ljungberg B, Albiges L, Bensalah K et al (2017) EAU Guidelines Renal Cell Carcinoma. https://uroweb.org/guideline/renal-cell-carcinoma. Accessed 21 Dec 2017
- 12.Stewart JH, Buccianti G, Agodoa L, Gellert R, McCredie MR, Lowenfels AB, Disney AP, Wolfe RA, Boyle P, Maisonneuve P (2003) Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 14(1):197–207CrossRefPubMedGoogle Scholar
- 25.Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, Copeland G, Finch JL, Fleissner ML, Goodman MT, Kahn A, Koch L, Lynch CF, Madeleine MM, Pawlish K, Rao C, Williams MA, Castenson D, Curry M, Parsons R, Fant G, Lin M (2011) Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306(17):1891–1901CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Gigante M, Neuzillet Y, Patard JJ, Tillou X, Thuret R, Branchereau J, Timsit MO, Terrier N, Boutin JM, Sallusto F, Karam G, Barrou B, Chevallier D, Mazzola CR, Delaporte V, Doeffler A, Kleinclauss F, Badet L, the members of the Comité de Cancerologie de l'Association Française d'Urologie (CCAFU) and Comité de Transplantation de l'Association Française d'Urologie (CTAFU) (2012) Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities? BJU Int 110(11 Pt B):E570–E573CrossRefPubMedGoogle Scholar
- 33.Hofmann JN, Schwartz K, Chow WH, Ruterbusch JJ, Shuch BM, Karami S, Rothman N, Wacholder S, Graubard BI, Colt JS, Purdue MP (2013) The association between chronic renal failure and renal cell carcinoma may differ between black and white Americans. Cancer Causes Control 24(1):167–174CrossRefPubMedGoogle Scholar
- 46.O'Neill JO, Edwards LB, Taylor DO (2006) Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25(10):1186–1191CrossRefPubMedGoogle Scholar
- 49.Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, Neylan JF, Korth-Bradley J, Goldberg-Alberts R, Maller ES, Sirolimus CONVERT Trial Study Group (2011) Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 92(3):303–310CrossRefPubMedGoogle Scholar